PubRank

Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)

Clinical Trial ID NCT00473928

PubWeight™ 19.83‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00473928

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immunology of age-related macular degeneration. Nat Rev Immunol 2013 2.14
2 STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012 1.89
3 Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014 1.55
4 New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2012 1.39
5 The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) 2010 1.29
6 The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol 2010 1.12
7 Recent developments in the treatment of age-related macular degeneration. J Clin Invest 2014 0.99
8 Therapeutic control of complement activation at the level of the central component C3. Immunobiology 2015 0.94
9 Polymorphisms in complement component 3 (C3F) and complement factor H (Y402H) increase the risk of postoperative neurocognitive dysfunction following carotid endarterectomy. J Neurol Neurosurg Psychiatry 2010 0.94
10 Applying complement therapeutics to rare diseases. Clin Immunol 2015 0.87
11 Complement pathway biomarkers and age-related macular degeneration. Eye (Lond) 2015 0.86
12 Future therapies of wet age-related macular degeneration. J Ophthalmol 2015 0.84
13 Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration. J Clin Med 2015 0.83
14 Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures. Exp Eye Res 2013 0.83
15 Present and possible therapies for age-related macular degeneration. ISRN Ophthalmol 2014 0.79
16 Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol 2016 0.78
17 Dry age-related macular degeneration: A currently unmet clinical need. Intractable Rare Dis Res 2012 0.78
18 Targeting inflammation in emerging therapies for genetic retinal disease. Int J Inflam 2013 0.77
19 New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics. J Med Chem 2014 0.76
Next 100